# US 7,838,006 B2 · Viral vaccine composition, process and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,838,006 B2
- Document ID: US7838006B2
- Status: Granted
- Kind: B2
- Application number: 12/102,564
- Filed: 2008-04-14
- Published: 2009-09-10
- Granted: 2010-11-23
- Earliest claimed: 2008-04-14
- Assignees: Immunitor USA Inc.
- Inventors: Vichai Jirathitikal; Aldar Bourinbaiar
- Web page: https://patentgrep.com/patent/US7838006B2

## CPC

- A61K 39/015: Hemosporidia antigens, e.g. Plasmodium antigens
- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/0006: {Contraceptive vaccins; Vaccines against sex hormones}
- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61K 2039/51: {comprising whole cells, viruses or DNA/RNA}
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/541: {Mucosal route}
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/552: {Veterinary vaccine}
- C12N 2710/14034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A composition for treating or preventing virus-induced infections is described, along with a process of producing the composition and methods of the composition's use. The composition comprises viral pathogen-infected cell or tissue, or malignantly or immunologically aberrant cells or tissues which has been reduced and/or denatured. The preferred composition is administered across a mucosal surface of an animal suffering or about suffer from infection. The composition is administered as preventive or therapeutic vaccine.

## Claims

### Claim 1

A composition comprising denatured hepatitis type B or type C viral pathogen, wherein the pathogens are denatured through a method comprising drying the pathogen and denaturing the resulting dried pathogen using heat alone, wherein the composition is formulated as an oral pill.

### Claim 2 (depends on 1)

The composition process of claim 1, wherein the hepatitis viral pathogen is hepatitis B virus.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the hepatitis viral pathogen is hepatitis C virus.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said composition is formulated without an immune adjuvant.

### Claim 5 (depends on 1)

The composition of claim 1, said composition further comprising hepatitis viral pathogen-infected denatured tissue.

### Claim 6

A hepatitis immunogen comprising heat denatured hepatitis virus type B and type C, wherein the hepatitis B virus and hepatitis C virus are denatured through a method comprising drying the hepatitis B virus and hepatitis C virus and denaturing the resulting dried viruses using heat alone to produce the immunogen, wherein the immunogen is formulated as an oral pill.

### Claim 7 (depends on 6)

The immunogen of claim 6, wherein said immunogen is formulated without an immune adjuvant.

### Claim 8 (depends on 6)

The immunogen of claim 6, wherein the immunogen comprised in said pill is between about 0.0000001% to about 20% by weight.

### Claim 9

An oral composition suitable for inducing an immune response in a subject, the composition comprising a first component comprising denatured hepatitis type B or type C viral pathogen, wherein the pathogens are denatured through a method comprising drying the pathogen and denaturing the resulting dried pathogen using heat alone, and a second component comprising a denatured pooled blood tissue from a host infected by hepatitis virus type B and type C.

### Claim 10 (depends on 9)

The oral composition of claim 9, said composition further comprising calcium or magnesium, or both.